# Radiation Oncology Referral

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Nelson Mandela (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML021-SYN-TD
- Date: 2001-03-10
- Fictional facility: St. Posthumous Health Center
- Fictional author: Thandiwe Mokoena, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- To: Pieter van Zyl, MD, Radiation Oncology
- Urgency: Routine, within four to six weeks

## Referral question

Man of 82 with newly diagnosed prostate adenocarcinoma, Grade Group 3, PSA 6.4 ng/mL, cT1c, NCCN unfavorable intermediate risk, found after a rising PSA on monitoring. Please advise on curative treatment, including radiotherapy with short-term androgen deprivation, and whether observation is reasonable at his age. **S**

## Questions for the consultant

1. Do you agree with the risk group, and is staging complete with the PSMA PET/CT?
2. What are his curative options at 82, and is observation a reasonable choice?
3. If radiotherapy is chosen, should androgen deprivation be added, for how long, and how should it start?
4. Does his earlier prostate operation change the choice of technique or his risk of urinary side effects?
5. What monitoring is needed during and after treatment, including PSA follow-up, and which parts should primary care manage?

## Pertinent history

Fit and independent; walks every morning. Decades ago he had an operation that removed part of the prostate for benign enlargement with urinary blockage. Treated tuberculosis in the past, with no symptoms since. A rise in PSA on routine monitoring led to a multiparametric MRI (28 mL gland with a resection defect; 9 mm PI-RADS 4 lesion in the left peripheral zone; no extraprostatic extension) and an MRI-ultrasound fusion transperineal biopsy: Gleason 4+3 in 1 of 2 targeted cores (30 percent) and Gleason 3+4 in 2 of 12 systematic cores; 3 of 14 cores positive. Digital rectal examination: smooth, no nodule. PSA 6.4 ng/mL, testosterone 412 ng/dL, hemoglobin 14.1 g/dL, eGFR 69, alkaline phosphatase 74 U/L, A1c 5.5 percent, LDL 112 mg/dL, 25-hydroxyvitamin D 26 ng/mL. IPSS 7. PHQ-9 score 4. No regular medicines. PSMA PET/CT ordered; DXA booked for the day of the consultation. **S**

- Nelson Rolihlahla Mandela was born in Mvezo, in the Eastern Cape, on 18 July 1918. **D**
- Mandela was convicted with seven co-accused in the Rivonia Trial on 11 June 1964 and sentenced to life imprisonment the next day. He was held on Robben Island, moved to Pollsmoor Prison on 31 March 1982 and to Victor Verster Prison near Paarl on 7 December 1988, and was released from Victor Verster on 11 February 1990. **D**
- In 1985 Mandela had prostate surgery while imprisoned. His urologist said in July 2001 that the gland had been enlarged and was causing a urinary blockage, and that part of it was removed. **D**
- Mandela was taken to hospital on 12 August 1988 and diagnosed with tuberculosis; public reports describe it as early tuberculosis, treated at the Constantiaberg Medi-clinic, after which he was moved to Victor Verster Prison. **D**
- His doctors said publicly in 2001 that he had been monitored regularly with the prostate-specific antigen (PSA) test, that a slight rise in the PSA led to a biopsy of the prostate, and that the biopsy confirmed microscopic cancer within the gland. News reports said the raised blood level was first found in November 2000. **D**
- Mandela was inaugurated as South Africa's first democratically elected president on 10 May 1994 and stepped down in 1999 after one term. **D**

4 later historical claims are omitted because they describe events after the index age. See the teaching note.

Baseline: PSA: 6.4 ng/mL (high); Total testosterone: 412 ng/dL; Hemoglobin: 14.1 g/dL; White cell count: 5.8 10*3/uL; Platelets: 226 10*3/uL; Sodium: 140 mmol/L; Potassium: 4.4 mmol/L; Fasting glucose: 94 mg/dL; Creatinine: 1.08 mg/dL; eGFR: 69 mL/min/1.73 m²; Calcium: 9.4 mg/dL; ALT: 18 U/L; Alkaline phosphatase: 74 U/L; Albumin: 4.1 g/dL; Hemoglobin A1c: 5.5%; Total cholesterol: 184 mg/dL; HDL cholesterol: 52 mg/dL; LDL cholesterol: 112 mg/dL; Triglycerides: 98 mg/dL; 25-hydroxyvitamin D: 26 ng/mL (low); PHQ-9: 4; IPSS total (0 to 35): 7. All results are synthetic.

BP 132/78 mmHg; pulse 68 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 97% on room air; weight 80.2 kg; BMI 23.9 kg/m². All vital signs are synthetic.

## Current medications

- No current medications. **S**

## Plan so far

- Staging for unfavorable intermediate-risk disease with PSMA PET/CT. Guideline: NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer (2026); CMID: Clinical Monitoring Intelligence Database, prostate cancer monograph (2026) **S**
- Distress screening at each visit, physical activity, and a written survivorship care plan. Guideline: Skolarus TA, et al. American Cancer Society prostate cancer survivorship care guidelines. CA Cancer J Clin 2014;64(4):225-249 (2014); CMID: Clinical Monitoring Intelligence Database, prostate cancer monograph (2026) **S**
